2017•Antimicrobial Agents and ChemotherapyOpen access

In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Ken B. Waites, Donna M. Crabb, Li Xiao, Lynn B. Duffy

Open full text 19 citations

Abstract

ABSTRACT Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates of Mycoplasma pneumoniae , Mycoplasma hominis , Mycoplasma genitalium , Ureaplasma parvum , and Ureaplasma urealyticum in comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MIC 90 s (μg/ml) were 0.125 ( M. pneumoniae ), 0.032 ( M. genitalium ), 2 ( M. hominis ), and 8 ( Ureaplasma species). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.

Open-access reader

About this research paper

What this paper is about

ABSTRACT Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates of Mycoplasma pneumoniae , Mycoplasma hominis , Mycoplasma genitalium , Ureaplasma parvum , and Ureaplasma urealyticum in comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MIC 90 s (μg/ml) were 0.125 ( M. pneumoniae ), 0.032 ( M. genitalium ), 2 ( M. hominis ), and 8 ( Ureaplasma species). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.

Why it matters

OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

ABSTRACT Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates of Mycoplasma pneumoniae , Mycoplasma hominis , Mycoplasma genitalium , Ureaplasma parvum , and Ureaplasma urealyticum in comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MIC 90 s (μg/ml) were 0.125 ( M. pneumoniae ), 0.032 ( M. genitalium ), 2 ( M. hominis ), and 8 ( Ureaplasma species). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.

Key concepts: Mycoplasma hominis, Microbiology, Ureaplasma, Ureaplasma urealyticum, Mycoplasma genitalium, Moxifloxacin, Mycoplasma, Mycoplasmataceae

Related papers

Back to paper searchBrowse research topicsOriginal source
In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas — Research Paper | ScholarLens